MedTrace Logo

Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

NCT06898424 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-24

No results posted yet for this study

Summary

This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.

Conditions

  • Alzheimer Type Dementia
  • Alzheimer's Disease (AD)

Interventions

BEHAVIORAL

Ketoflex 12/3 Diet

plant-based ketogenic diet combined with intermittent fasting (12/3)

Sponsors & Collaborators

  • Prof. Lutfu Hanoglu, MD

    lead OTHER

Principal Investigators

  • Lütfü Hanoğlu, Prof. MD · Medipol University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-09-30
Completion
2024-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06898424 on ClinicalTrials.gov